Correction

In the AHA Scientific Statement, “Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention” by Rosendorff et al, which published in the May 29, 2007, issue of the journal (Circulation. 2007;115:2761–2788), the following changes are needed:

1. On page 2778, in the second column, first paragraph, the phrase “or hospitalization” should be added to the penultimate sentence to read, “In the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial, mortality or hospitalization was significantly lower in patients with HF who received a high dose of lisinopril (32.5 to 35 mg/d) than in those treated with a low dose of lisinopril (2.5 to 5 mg/d).¹⁶⁹”

2. On page 2779, at the bottom of the first column, the sentence beginning “Although all 3 of these agents…” should read, “Although all 3 of these agents (metoprolol, carvedilol, and bisoprolol) are beneficial in patients with HF, the Carvedilol or Metoprolol European Trial (COMET) demonstrated a 17% greater mortality reduction in favor of carvedilol compared with metoprolol, with mean daily doses of 42 and 85 mg/d, respectively.¹⁸³”

These changes have been made in the current online version of this article.